AS Grindeks jaunu vielu izp\u0113t\u0113 invest\u0113s 460 000 latu. L\u012bdzek\u013ci tiks atv\u0113l\u0113ti antii\u0161\u0113misko vielu izp\u0113tei, ko veiks Latvijas Organisk\u0101s sint\u0113zes instit\u016bts, kas ir Grindeks akad\u0113miskais partneris.<\/p>\n\n\n\n
K\u0101 atkl\u0101ja Grindeks P\u0113tniec\u012bbas un att\u012bst\u012bbas departamenta vad\u012bt\u0101js Ilm\u0101rs Ston\u0101ns, projekta laik\u0101 Grindeks sadarbosies ar Organisk\u0101s sint\u0113zes instit\u016btu, izmantojot abu pu\u0161u kompetences, veiks p\u0113t\u012bjumus jaunu antii\u0161\u0113misku vielu jom\u0101.<\/p>\n\n\n\n
\u201cAntii\u0161\u0113misku vielu izp\u0113te ir b\u016btiska jaunu z\u0101\u013cu izstr\u0101d\u0113 sirds un asinsvadu, k\u0101 ar\u012b centr\u0101lo nervu sist\u0113mu ietekm\u0113jo\u0161u slim\u012bbu \u0101rst\u0113\u0161anai. Abas \u0161\u012bs terapeitisk\u0101s grupas ir strat\u0113\u0123iskas uz\u0146\u0113muma kop\u0113j\u0101 produktu kl\u0101st\u0101,\u201d nor\u0101d\u012bja Ston\u0101ns.<\/p>\n\n\n\n
Vi\u0146\u0161 ar\u012b atz\u012bm\u0113ja, ka p\u0113t\u012bjuma rezult\u0101ti kalpos par pamatu jaunu z\u0101\u013cu izstr\u0101dei un tiks publiskoti gan patentu, gan zin\u0101tnisko publik\u0101ciju veid\u0101. L\u012bdz publik\u0101ciju br\u012bdim inform\u0101cija ir konfidenci\u0101la.<\/p>\n\n\n\n
Invest\u012bcijas, kas paredz\u0113tas \u0161im p\u0113t\u012bjumam, ir tikai neliela da\u013ca no jauna medikamenta rad\u012b\u0161anas izmaks\u0101m. Konkr\u0113tajam p\u0113t\u012bjuma posmam ir atv\u0113l\u0113ts pusgads. K\u0101 zin\u0101ms, jauna ori\u0123in\u0101lprepar\u0101ta izstr\u0101des un ievie\u0161anas laiks ilgst aptuveni septi\u0146us l\u012bdz desmit gadus, teica Grindeks P\u0113tniec\u012bbas un att\u012bst\u012bbas departamenta vad\u012bt\u0101js.<\/p>\n\n\n\n
K\u0101 zi\u0146ots, Grindeks darb\u012bbas rezult\u0101ti \u0161\u012b gada pirmajos divos m\u0113ne\u0161os, sal\u012bdzinot ar t\u0101du pa\u0161u periodu p\u0113rn, nodro\u0161in\u0101ju\u0161i apgroz\u012bjuma pieaugumu par 5%. Uz\u0146\u0113mums \u0161ogad pl\u0101no sasniegt teju 100 miljonu latu apgroz\u012bjumu un pe\u013c\u0146u apm\u0113ram 12 miljonu latu apm\u0113r\u0101.<\/p>\n\n\n\n
Grindeks \u0161ogad att\u012bst\u012bb\u0101 pl\u0101no invest\u0113t vismaz \u010detrus miljonus latu, liecina uz\u0146\u0113muma pazi\u0146ojums bir\u017e\u0101 \u201cNASDAQ OMX Riga\u201d.<\/p>\n\n\n\n
Liel\u0101kais invest\u012bciju apjoms tiks virz\u012bts produktu kvalit\u0101tes nodro\u0161in\u0101\u0161anai. V\u0113rien\u012bg\u0101kais invest\u012bciju projekts ir mikrobiolo\u0123ijas laboratorijas renov\u0101cija un apr\u012bko\u0161ana ar jaun\u0101m tehnolo\u0123iskaj\u0101m iek\u0101rt\u0101m. Pl\u0101not\u0101s projekta izmaksas 2013.gad\u0101 b\u016bs viens miljons latu.<\/p>\n\n\n\n
Jau zi\u0146ots, ka koncerna apgroz\u012bjums 2012.gad\u0101 bija 82,7 miljoni latu, kas ir par 13,1 miljonu latu jeb par 18,8% vair\u0101k nek\u0101 2011.gad\u0101. Savuk\u0101rt koncerna neto pe\u013c\u0146a, kas attiecin\u0101ma uz m\u0101tessabiedr\u012bbas akcion\u0101riem, 2012.gad\u0101 bija 9,6 miljoni latu, kas, sal\u012bdzinot ar 2011.gadu, ir palielin\u0101jusies par 2,9 miljoniem latu jeb 43,3%, liecina \u201cNASDAQ OMX Riga\u201d iesniegtie 2012.gada nerevid\u0113tie konsolid\u0113tie finan\u0161u p\u0101rskati.<\/p>\n\n\n\n
Ain\u0101rs Sauka, Nozare.lv<\/p>\n","protected":false},"excerpt":{"rendered":"
AS Grindeks jaunu vielu izp\u0113t\u0113 invest\u0113s 460 000 latu. L\u012bdzek\u013ci tiks atv\u0113l\u0113ti antii\u0161\u0113misko vielu izp\u0113tei, ko veiks Latvijas Organisk\u0101s sint\u0113zes instit\u016bts, kas ir Grindeks akad\u0113miskais…<\/p>\n","protected":false},"author":3,"featured_media":6601,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[2],"tags":[],"class_list":["post-1243","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-jaunums"],"acf":[],"_links":{"self":[{"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/posts\/1243","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/comments?post=1243"}],"version-history":[{"count":0,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/posts\/1243\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/media\/6601"}],"wp:attachment":[{"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/media?parent=1243"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/categories?post=1243"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/tags?post=1243"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}